Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 63% Improvement Relative Risk c19hcq.org Aparisi et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Prospective study of 654 patients in Spain Lower mortality with HCQ (p=0.008) Aparisi et al., medRxiv, doi:10.1101/2020.10.06.20207092 Favors HCQ Favors control
Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19
Aparisi et al., medRxiv, doi:10.1101/2020.10.06.20207092 (Preprint)
Aparisi et al., Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19, medRxiv, doi:10.1101/2020.10.06.20207092 (Preprint)
Oct 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 654 hospitalized patients focused on low-density lipoprotein cholesterol levels, also showing results for HCQ with 605 HCQ patients, unadjusted 30 day mortality relative risk RR 0.37, p = 0.008. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 63.0% lower, RR 0.37, p = 0.008, treatment 122 of 605 (20.2%), control 27 of 49 (55.1%), NNT 2.9.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Aparisi et al., 8 Oct 2020, prospective, Spain, preprint, 18 authors, average treatment delay 7.0 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.10.06.20207092; this version posted October 8, 2020. The copyright holder has placed this preprint (which was not certified by peer review) in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose without crediting the original authors. Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19 Álvaro Aparisi, MD1#; Carolina Iglesias-Echeverría, MD1; Cristina Ybarra-Falcón, MD1; Iván Cusácovich, MD, PhD3; Aitor Uribarri MD, PhD1 ; Mario García-Gómez, MD1 ; Raquel Ladrón MD1; Raúl Fuertes ; MD⁴; Jordi Candela, MD1; Williams Hinojosa, MD1; Carlos Dueñas, MD3; Roberto González, MD, PhD3; Leonor Nogales, MD5; Dolores Calvo MD6; Manuel Carrasco-Moraleja, MSc1; J. Alberto San Román, MD, PhD1,2; Ignacio J.Amat-Santos, MD, PhD1,2 ; David Andaluz-Ojeda, MD, PhD5* ¹Cardiology Department, Hospital Clínico Universitario, Valladolid, Spain ²CIBERCV, Cardiology Department, Hospital Clínico Universitario, Valladolid, Spain 3 Internal Medicine Deparment, Hospital Clínico Universitario de Valladolid, Spain 4 5 Medicine School, University of Valladolid, Valladolid, Spain Intensive Care Unit Department, Hospital Clínico Universitario de Valladolid, Spain 6 Clinical analysis department, Hospital Clínico Universitario de Valladolid, Spain Short title: LDL levels in COVID-19 Word count: 3,010 Abstract word count: 200 Conflicts of interest: None. Financial sources: This work was partially funded by Gerencia Regional de Salud de Castilla y León under grant number GRS COVID 111/A/20 and GRS COVID 108/A/20 Ethics of protocol: According to the Declaration of Helsinki, the local ethics committee approved this study. *Corresponding author: David Andaluz Ojeda, MD, Ph.D. Intensive Care Department. Hospital Clínico Universitario de Valladolid, Spain. Ramón y Cajal 3. 47005. Valladolid. Spain. Telephone. 0034 983 42 00 26. Fax. 0034 983 25 53 05 e-mail: dandaluz@saludcastillayleon.es 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.10.06.20207092; this version posted October 8, 2020. The copyright holder has placed this preprint (which was not certified by peer review) in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose without crediting the original authors. STRUCTURED ABSTRACT Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the sole causative agent of coronavirus infectious disease-19 (COVID-19). Methods: We performed a retrospective single-center study of consecutively admitted patients between March 1st and May 15th, 2020, with a definitive diagnosis of SARS-CoV-2 infection. The primary end-point was to evaluate the association of lipid markers with 30-days all-cause mortality in COVID-19. Results: A total of 654 patients were enrolled, with an estimated 30-day mortality of 22.8% (149 patients). Non-survivors had lower total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c) levels during the entire course of the disease with complete resolution among survivors. Both showed a significant inverse correlation with inflammatory markers and a positive correlation with lymphocyte count. In a multivariate analysis, LDL-c ≤..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit